Search results for " Parkinson Disease"

showing 10 items of 27 documents

Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease

2009

BACKGROUND: The neural mechanisms and the circuitry involved in levodopa-induced dyskinesia (LID) are still partially obscure. LID can be considered the consequence of an abnormal pattern or code of activity that originates and is conveyed from the basal ganglia to the thalamus and the cortical motor areas. However, not only striatothalamocortical motor circuits but also other interconnected pathways could be implicated in its pathogenesis. METHODS: In a series of experiments, we applied repetitive transcranial magnetic stimulation (rTMS) over the lateral cerebellum in a group of patients with advanced Parkinson disease, to investigate whether modulation of cerebellothalamocortical circuits…

Dyskinesia Drug-InducedLevodopaCerebellummedicine.medical_treatmentCTBStmSeverity of Illness IndexrehabilitationNOLevodopaNeural PathwaySeverity of Illness Index; Analysis of Variance; Levodopa; Dyskinesia Drug-Induced; Humans; Cerebellum; Aged; Neural Inhibition; Thalamus; Motor Cortex; Parkinson Disease; Evoked Potentials Motor; Neural Pathways; Middle Aged; Neuronal Plasticity; Transcranial Magnetic StimulationThalamusCerebellumNeural PathwaysBasal gangliamedicineHumansEvoked PotentialsThalamuAgedAnalysis of VarianceNeuronal PlasticityDyskinesiaMotor CortexNeural InhibitionParkinson DiseaseMiddle AgedEvoked Potentials MotorTranscranial Magnetic StimulationAged; Analysis of Variance; Cerebellum; Drug-Induced Dyskinesia; Evoked Potentials; Motor; Humans; Levodopa; Middle Aged; Motor Cortex; Neural Inhibition; Neural Pathways; Neuronal Plasticity; Parkinson Disease; Severity of Illness Index; Thalamus; Transcranial Magnetic StimulationTranscranial magnetic stimulationmedicine.anatomical_structureMotorDyskinesiaDrug-Inducedparkinson's diseaseSettore MED/26 - NeurologiaDrug-Induced DyskinesiaNeurology (clinical)Primary motor cortexmedicine.symptomPsychologyNeuroscienceHumanMotor cortexmedicine.drugNeurology
researchProduct

Factors influencing psychological well-being in patients with Parkinson's disease.

2017

Background Both motor and non-motor symptoms could contribute to significant deterioration of psychological well-being in patients with Parkinson's disease (PD). However, its assessment has been only indirectly evaluated using tools based on health-related quality of life (HRQoL), such as the PDQ-39 scale. Objectives To evaluate psychological well-being in PD using a specific tool of assessment, the Psychological Well-being Scale (PWS), and its clinical correlates. Methods This article reports data of patients' perception of health state, as measured by means of the PWS, from an epidemiological, cross-sectional study conducted in Italian PD patients (FORTE Study). We tested possible relatio…

Genetics and Molecular Biology (all)MaleParkinson's diseaseEmotionsPoison controlSocial Scienceslcsh:MedicinePathology and Laboratory MedicineBiochemistrySeverity of Illness IndexAged; Depression; Fatigue; Female; Humans; Italy; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)0302 clinical medicineMathematical and Statistical TechniquesQuality of lifeSurveys and QuestionnairesMedicine and Health SciencesMedicinePsychologySurveys and Questionnaire030212 general & internal medicinelcsh:ScienceDepression (differential diagnoses)FatigueMultidisciplinaryMovement DisordersDepressionNeurodegenerative DiseasesParkinson DiseaseMiddle AgedPsychiatric Status Rating ScalehumanitiesNeurologyItalyPhysical SciencesFemaleStatistics (Mathematics)Clinical psychologyResearch ArticleHumanResearch and Analysis Methods03 medical and health sciencesSigns and SymptomsDiagnostic MedicineSeverity of illnessInjury preventionMental Health and PsychiatryHumansStatistical MethodsAgedPsychiatric Status Rating Scalesparkinson's disease quality of lifeAnalysis of VarianceBiochemistry Genetics and Molecular Biology (all)business.industryMood Disorderslcsh:RBeck Depression InventoryBiology and Life Sciencesmedicine.diseaseHealth CareAgricultural and Biological Sciences (all)Psychological well-beingAged; Depression; Fatigue; Female; Humans; Italy; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Quality of Life; Severity of Illness Index; Surveys and QuestionnairesQuality of Lifelcsh:QbusinessSleep Disorders030217 neurology & neurosurgeryMathematicsPLoS ONE
researchProduct

[Exercices program and rehabilitation of motor disorders in Parkinson's disease].

2000

International audience; As long as motor disorders are controlled by DOPAtherapy, exercise programs and rehabilitation would not appear to be essential for patients suffering from Parkinson's disease. Such measures do become necessary however when secondary occurrence of motor decline develops. Physical medicine and rehabilitation have not been really involved in Parkinson's disease and few articles have assessed the value of these programs. In fact, controlled randomized studies have faced two kinds of methodological difficulties, those due to rehabilitation practices, and those due to Parkinson's disease specificity, especially similarities between groups for Hoehn and Yahr stage at study…

MESH: HumansMovement DisordersMESH : Humans[SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesParkinson DiseaseMESH : Exercise TherapyExercise Therapy[ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesMESH : Parkinson DiseaseMESH : Physical Therapy ModalitiesMESH : Movement DisordersMESH: Exercise TherapyHumans[SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesMESH: Movement DisordersMESH: Parkinson DiseasePhysical Therapy ModalitiesMESH: Physical Therapy ModalitiesRevue neurologique
researchProduct

Effects of Substantia Nigra pars compacta lesion on the behavioral sequencing in the 6-OHDA model of Parkinson’s disease

2019

The basal ganglia circuitry plays a crucial role in the sequential organization of behavior. Here we studied the behavioral structure of the animals after 21 days of 6-OHDA-induced lesion of the dopaminergic nigrostriatal system. Frequencies and durations of individual components of the behavioral repertoire were calculated; moreover, whether a temporal organization of the activity was present, it was investigated by using T-pattern analysis, a multivariate approach able to detect the real-time sequential organization of behavior. Six sham-depleted and six rats with unilateral 6−OHDA-lesion of the Substantia Nigra pars compacta were used. As to quantitative evaluations, the comparison betwe…

MaleParkinson's diseaseDopamineParkinson's diseaseSubstantia nigra6-OHDABiologyT-pattern analysisSettore BIO/09 - FisiologiaRats Sprague-DawleyLesion03 medical and health sciencesBehavioral Neuroscience0302 clinical medicineSubthalamic NucleusSniffingDopamineBasal gangliamedicine6-OHDA; Basal ganglia; Dopamine; Parkinson's disease; Substantia Nigra pars compacta; T-pattern analysis; Animals; Behavior Animal; Dopamine; Male; Oxidopamine; Parkinson Disease; Pars Compacta; Rats Sprague-Dawley; Substantia Nigra; Subthalamic NucleusAnimalsOxidopaminePars Compacta030304 developmental biologyBehavior0303 health sciencesBehavior AnimalAnimalPars compactaDopaminergicT-pattern analysiParkinson Diseasemedicine.diseaseRatsSubstantia Nigranervous system6-OHDA; Basal ganglia; Dopamine; Parkinson's disease; Substantia Nigra pars compacta; T-pattern analysis; Behavioral NeuroscienceBasal gangliaSprague-DawleySubstantia Nigra pars compactamedicine.symptomNeuroscience030217 neurology & neurosurgerymedicine.drugBehavioural Brain Research
researchProduct

Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort

2021

AbstractAim of the study was to evaluate possible associations between cognitive dysfunctions and development of Levodopa Induced Dyskinesia (LID). PD patients from the Parkinson’s disease Cognitive impairment Study cohort who underwent a baseline and follow-up neuropsychological evaluations were enrolled. Mild Cognitive Impairment (PD-MCI) was diagnosed according to MDS level II criteria. The following cognitive domains were evaluated: episodic memory, attention, executive function, visuo-spatial function and language. A domain was considered as impaired when the subject scored 2 standard deviation below normality cut-off values in at least one test for each domain. Levodopa equivalent dos…

Male0301 basic medicineDyskinesia Drug-InducedLevodopamedicine.medical_specialtyParkinson's diseaseScienceNeuropsychological TestsSeverity of Illness IndexArticleCohort StudiesLevodopaExecutive Function03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansAttentionCognitive DysfunctionLongitudinal StudiesAgedProportional Hazards ModelsLevodopa-induced dyskinesiaMultidisciplinarybusiness.industryQRNeuropsychologyParkinson DiseaseCognitionMiddle Agedmedicine.diseaseAged Attention Cognitive Dysfunction Cohort Studies Dyskinesia Drug-Induced Executive Function Female Humans Levodopa Longitudinal Studies Male Middle Aged Neuropsychological Tests Parkinson Disease Proportional Hazards Models Severity of Illness Index030104 developmental biologyNeurologyRisk factorsDyskinesiaCohortMedicineFemalemedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugCohort studyScientific Reports
researchProduct

Early DEtection of wEaring off in Parkinson disease: The DEEP study

2014

Assessing the frequency of Wearing-Off (WO) in Parkinson's disease (PD) patients, and its impact on Quality of Life (QoL). METHODS: Consecutive ambulatory patients, who were on dopaminergic treatment for ≥ 1 year, were included in this multicentre, observational cross-sectional study. In a single visit, WO was diagnosed based on neurologist assessment as well as using the validated Italian version of a patient self-rated 19-question Wearing-Off Questionnaire (WOQ-19); WO was defined for scores ≥ 2. QoL was evaluated by the 8-item Parkinson's Disease Questionnaire (PDQ-8). RESULTS: 617 subjects were included, with a mean anti-Parkinson treatment duration of 6.6 ± 4.6 years, 87.2% were on lev…

QuestionnairesAdultMaleQuality of lifeLevodopamedicine.medical_specialtyPediatricsParkinson's diseaseTreatment durationParkinson's diseaseEarly detectionDiseaseLevodopaAntiparkinson AgentsQuality of lifeSurveys and Questionnairesmedicine80 and overHumansWearing-offAgedAged 80 and overParkinson's disease; Quality of life; Wearing-off; Wearing-off questionnairebusiness.industryParkinson DiseaseParkinson's disease; quality of life; wearing-off; wearing-off questionnaireMiddle Agedmedicine.diseaseLevodopa; Questionnaires; Parkinson's disease; Humans; Wearing-off; Quality of Life; Aged; Antiparkinson Agents; Cross-Sectional Studies; Wearing-off questionnaire; Parkinson Disease; Aged 80 and over; Adult; Middle Aged; Male; Female; Quality of lifeCross-Sectional StudiesNeurologyAmbulatoryPhysical therapyWearing-off questionnaireObservational studyFemaleSettore MED/26 - NeurologiaNeurology (clinical)Geriatrics and Gerontologybusinessmedicine.drug
researchProduct

Pressure effects on α-synuclein amyloid fibrils: An experimental investigation on their dissociation and reversible nature

2017

α–synuclein amyloid fibrils are found in surviving neurons of Parkinson's disease affected patients, but the role they play in the disease development is still under debate. A growing number of evidences points to soluble oligomers as the major cytotoxic species, while insoluble fibrillar aggregates could even play a protection role. In this work, we investigate α–synuclein fibrils dissociation induced at high pressure by means of Small Angle X-ray Scattering and Fourier Transform Infrared Spectroscopy. Fibrils were produced from wild type α–synuclein and two familial mutants, A30P and A53T. Our results enlighten the different reversible nature of α–synuclein fibrils fragmentati…

0301 basic medicineSmall AngleAmyloidHigh-pressureMutantBiophysicsmacromolecular substances010402 general chemistryFibril01 natural sciencesBiochemistryDissociation (chemistry)Scattering03 medical and health scienceschemistry.chemical_compoundX-Ray DiffractionScattering Small AngleSpectroscopy Fourier Transform InfraredPressureHumansPoint MutationFourier transform infrared spectroscopyMolecular BiologySpectroscopyAlpha-synucleinAmyloid; FTIR; High-pressure; SAXS; α-synuclein; Amyloid; Humans; Parkinson Disease; Point Mutation; Pressure; Scattering Small Angle; Solubility; Spectroscopy Fourier Transform Infrared; X-Ray Diffraction; alpha-Synuclein; Biophysics; Biochemistry; Molecular BiologySmall-angle X-ray scatteringWild typeα-synucleinParkinson DiseaseSAXSAmyloid fibril0104 chemical sciences?-synucleinCrystallography030104 developmental biologyBiophysicchemistryFTIRSolubilityFourier Transform InfraredBiophysicsalpha-SynucleinHuman
researchProduct

Neuronal cell cycle: the neuron itself and its circumstances.

2015

Neurons are usually regarded as postmitotic cells that undergo apoptosis in response to cell cycle reactivation. Nevertheless, recent evidence indicates the existence of a defined developmental program that induces DNA replication in specific populations of neurons, which remain in a tetraploid state for the rest of their adult life. Similarly, de novo neuronal tetraploidization has also been described in the adult brain as an early hallmark of neurodegeneration. The aim of this review is to integrate these recent developments in the context of cell cycle regulation and apoptotic cell death in neurons. We conclude that a variety of mechanisms exists in neuronal cells for G1/S and G2/M check…

ApoptosisBrdU 5-bromo-2′-deoxyuridineReviewp75NTR neurotrophin receptor p75Nervous SystemG0 quiescent stateCKI Cdk-inhibitorNeuronsCell DeathNeurodegenerationCell CycleapoptosisNeurodegenerative DiseasesCell cycleCell biologymedicine.anatomical_structureInk inhibitor of kinaseBDNF brain-derived neurotrophic factorp38MAPK p38 mitogen-activated protein kinaseG2 growth phase 2Programmed cell deathS-phasePD Parkinson diseaseRb RetinoblastomaMcm2 minichromosome maintenance 2PCNA proliferating cell nuclear antigenMitosisContext (language use)BiologyCdk cyclin-dependent kinaseCNS central nervous systemS-phase synthesis phase.Cip/Kip cyclin inhibitor protein/kinase inhibitor proteinmedicineAnimalsHumansMolecular BiologyMitosisTetraploidAD Alzheimer diseasecell cycle re-entryDNA replicationCell BiologyNeuronmedicine.diseaseG1 growth phase 1neuronRGCs retinal ganglion cellsCell cycle re-entrytetraploidnervous systemApoptosisNeuronDevelopmental BiologyCell cycle (Georgetown, Tex.)
researchProduct

rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease

2005

The neural mechanisms and circuitry involved in levodopa-induced dyskinesia are unclear. Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion. rTMS at 1 Hz was observed to markedly reduce drug-induced dyskinesias, whereas 5-Hz rTMS induced a slight but not significant increase.

MaleDyskinesia Drug-InducedApomorphinemedicine.medical_treatmentDopamineNeurological disorderNOCentral nervous system diseaseDegenerative diseasemental disordersNeural PathwaysmedicineHumansAgedSupplementary motor areaDyskinesiabusiness.industryDyskinesia Drug-Induced; Treatment Outcome; Male; Middle Aged; Female; Humans; Parkinson Disease; Motor Cortex; Recovery of Function; Apomorphine; Dopamine Agonists; Neural Pathways; Aged; Transcranial Magnetic Stimulation; DopamineMotor CortexParkinson DiseaseRecovery of FunctionMiddle Agedmedicine.diseaseSMA*Transcranial Magnetic Stimulationnervous system diseasesTranscranial magnetic stimulationApomorphinemedicine.anatomical_structureTreatment OutcomeDyskinesiaDrug-InducedDopamine AgonistsFemaleSettore MED/26 - NeurologiaNeurology (clinical)medicine.symptombusinessNeurosciencemedicine.drug
researchProduct

CLINICAL EFFECTS OF DIFFERENT MONTAGES OF TRANSCRANIAL DIRECT CURRENT STIMULATION IN PATIENTS WITH PARKINSON’DISEASE

2014

tDCS Parkinson Disease
researchProduct